These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
322 related articles for article (PubMed ID: 19843279)
1. Successful implementation of a national HLA-B*5701 genetic testing service in Canada. Lalonde RG; Thomas R; Rachlis A; Gill MJ; Roger M; Angel JB; Smith G; Higgins N; Trottier B Tissue Antigens; 2010 Jan; 75(1):12-8. PubMed ID: 19843279 [TBL] [Abstract][Full Text] [Related]
2. A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase. Chui CK; Brumme ZL; Brumme CJ; Yip B; Phillips EJ; Montaner JS; Harrigan PR Clin Infect Dis; 2007 Jun; 44(11):1503-8. PubMed ID: 17479950 [TBL] [Abstract][Full Text] [Related]
3. Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicine. Guo Y; Shi L; Hong H; Su Z; Fuscoe J; Ning B Sci China Life Sci; 2013 Feb; 56(2):119-24. PubMed ID: 23393027 [TBL] [Abstract][Full Text] [Related]
6. Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience. Waters LJ; Mandalia S; Gazzard B; Nelson M AIDS; 2007 Nov; 21(18):2533-4. PubMed ID: 18025891 [TBL] [Abstract][Full Text] [Related]
7. A sensitive and rapid alternative to HLA typing as a genetic screening test for abacavir hypersensitivity syndrome. Martin AM; Krueger R; Almeida CA; Nolan D; Phillips E; Mallal S Pharmacogenet Genomics; 2006 May; 16(5):353-7. PubMed ID: 16609367 [TBL] [Abstract][Full Text] [Related]
8. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Mallal S; Nolan D; Witt C; Masel G; Martin AM; Moore C; Sayer D; Castley A; Mamotte C; Maxwell D; James I; Christiansen FT Lancet; 2002 Mar; 359(9308):727-32. PubMed ID: 11888582 [TBL] [Abstract][Full Text] [Related]
9. Current trends in screening across ethnicities for hypersensitivity to abacavir. Rodriguez-Nóvoa S; Soriano V Pharmacogenomics; 2008 Oct; 9(10):1531-41. PubMed ID: 18855539 [TBL] [Abstract][Full Text] [Related]
10. Incidence of abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected patients in Taiwan. Sun HY; Hung CC; Lin PH; Chang SF; Yang CY; Chang SY; Chang SC J Antimicrob Chemother; 2007 Sep; 60(3):599-604. PubMed ID: 17631508 [TBL] [Abstract][Full Text] [Related]
11. Are mutations in HIV type-1 reverse transcriptase 245 codon predictive of abacavir hypersensitivity reaction? Bracciale L; Santangelo R; Fanti I; Prosperi M; Colafigli M; Di Giambenedetto S; Marchetti S; Di Franco A; Cauda R; De Luca A Antivir Ther; 2009; 14(1):99-101. PubMed ID: 19320242 [TBL] [Abstract][Full Text] [Related]
12. HLA-B*5701 screening for susceptibility to abacavir hypersensitivity. Lucas A; Nolan D; Mallal S J Antimicrob Chemother; 2007 Apr; 59(4):591-3. PubMed ID: 17317695 [TBL] [Abstract][Full Text] [Related]
13. [Correlation, in previously treated HIV-1 positive patients, between hypersensitivity reaction to abacavir and the presence of the HLA-B*5701 allele]. Pérez Prior N; Rocher Milla A; Soler Company E; Flores Cid J; Sarria Chust B Farm Hosp; 2009; 33(3):155-60. PubMed ID: 19712599 [TBL] [Abstract][Full Text] [Related]
14. Use of patch testing for the diagnosis of abacavir-related hypersensitivity reaction in HIV patients. Giorgini S; Martinelli C; Tognetti L; Carocci A; Giuntini R; Mastronardi V; Torricelli F; Leoncini F; Lotti T Dermatol Ther; 2011; 24(6):591-4. PubMed ID: 22515676 [TBL] [Abstract][Full Text] [Related]
15. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. Schackman BR; Scott CA; Walensky RP; Losina E; Freedberg KA; Sax PE AIDS; 2008 Oct; 22(15):2025-33. PubMed ID: 18784465 [TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of HLA-B*5701 typing in the prevention of hypersensitivity to abacavir in HIV+ patients in Spain. Nieves Calatrava D; Calle-Martín Ode L; Iribarren-Loyarte JA; Rivero-Román A; García-Bujalance L; Pérez-Escolano I; Brosa-Riestra M Enferm Infecc Microbiol Clin; 2010 Nov; 28(9):590-5. PubMed ID: 20144493 [TBL] [Abstract][Full Text] [Related]
17. Abacavir hypersensitivity reaction: an update. Hughes CA; Foisy MM; Dewhurst N; Higgins N; Robinson L; Kelly DV; Lechelt KE Ann Pharmacother; 2008 Mar; 42(3):387-96. PubMed ID: 18303141 [TBL] [Abstract][Full Text] [Related]
18. Absence of human leukocyte antigen-B*57:01 amongst patients on antiretroviral therapy in Nigeria: Implications for use of abacavir. Agbaji OO; Akanbi MO; Otoh I; Agaba PA; Akinsola R; Okolie V; Ugoagwu PO; Babadoko AA; Adediran A; Finomo FO; Abah JO; Muktar HM; Akanmu AS Niger Postgrad Med J; 2019; 26(4):195-198. PubMed ID: 31621657 [TBL] [Abstract][Full Text] [Related]
19. Prevalence of HLA-B*57:01 allele in Argentinean HIV-1 infected patients. Moragas M; Belloso WH; Baquedano MS; Gutierrez MI; Bissio E; Larriba JM; Fay F; Aulicino P; Gurevich JM; Yaunguzian MF; Maldonado AC; Falistocco C; Sen L; Mangano A Tissue Antigens; 2015 Jul; 86(1):28-31. PubMed ID: 25922880 [TBL] [Abstract][Full Text] [Related]
20. Introduction of pharmacogenetic screening for the human leucocyte antigen (HLA) B*5701 variant in Polish HIV-infected patients. Parczewski M; Leszczyszyn-Pynka M; Wnuk A; Urbañska A; Fuksiñska K; Bander D; Boroñ-Kaczmarska A HIV Med; 2010 May; 11(5):345-8. PubMed ID: 20070406 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]